MedTrace Logo

Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing

NCT03932799 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5411

Last updated 2023-09-28

Study results available
· View outcomes & findings →

Summary

This study examines the comparative effectiveness of opioid review programs in reducing unsafe opioid prescribing in two states: prospective prior authorization (PA) with hard stops in Washington and retrospective review (RR) with prescriber notification in Ohio.

Conditions

  • Opioid Use
  • Opioid-Related Disorders

Interventions

OTHER

Prospective prior authorization (PA) with hard stops in Washington

Under Washington regulatory procedures, payment for any opioid prescription billed beyond six weeks after the injury is denied unless the prescriber has submitted a checklist attesting to completion of all best practices from the regulations/guidelines.Thus, the Washington intervention is prospective and includes a "hard stop" subject to an insurer's decision based on regulatory authority.

OTHER

Retrospective review (RR) with prescriber notification in Ohio

In Ohio an automated report identifies new opioid prescriptions beyond the acute phase. Ohio Workers' Compensation pharmacy and clinical staff review the medical record at 12 weeks to determine whether best practices were met. If not, the prescriber is notified via letter, and cases are reviewed again at 16 weeks. If best practices have still not been met, the prescriber and worker are notified via letter that opioid coverage will end in 4 weeks. The Ohio program relies on retrospective chart review and communication of best practices to prescribers.

Sponsors & Collaborators

Principal Investigators

  • Gary M Franklin, MD · University of Washington

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-06
Primary Completion
2022-03-31
Completion
2022-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03932799 on ClinicalTrials.gov